Guillain-Barre syndrome is the most common cause of acute flaccid paralysis in children. The incidence is lower in children than in adults, and it is especially rare in children younger than 2 years of age. Major precipitants of Guillain-Barre syndrome include *Campylobacter*, *Cytomegalovirus*, Epstein-Barr virus, *Mycoplasma pneumoniae*, and influenza-like illnesses. However, there are only a few reports of Guillain-Barre syndrome accompanied by hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infections (Epstein-Barr virus-hemophagocytic lymphohistiocytosis).

We present a case of Guillain-Barre syndrome associated with Epstein-Barr virus-hemophagocytic lymphohistiocytosis. In addition, we analyzed the data of patients with Guillain-Barre syndrome associated with Epstein-Barr virus infection by conducting a review of the literature using medical databases to investigate the clinicopathological features.

Case Report {#section1-2329048X15620641}
===========

A 16-month-old girl had a 5-day history of fever prior to admission to a local hospital. The diagnosis with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis was confirmed by hemophagocytosis in her bone marrow sample and a clonally expanded population of Epstein-Barr virus-infected CD8+ T cells. Laboratory data on admission were as follows: white blood cell, 23.9 × 10^9^/L; hemoglobin, 10.5 g/dL; platelet count, 4.7 × 10^9^/L; aspartate aminotransferase, 834 IU/L; alanine aminotransferase, 215 IU/L; lactate dehydrogenase, 4340 IU/L; ferritin, 77 597 ng/mL; Epstein-Barr virus capsid antigen immunoglobulin M titer, 20; Epstein-Barr virus capsid antigen immunoglobulin G titer, 40; Epstein-Barr virus-associated nuclear antigen, negative; and Epstein-Barr virus DNA (in peripheral blood), positive (1.3 × 10^6^ copies/1.0 × 10^6^ cells). Treatment with dexamethasone (10 mg/m^2^/day) and oral cyclosporin A (6 mg/kg/day) was promptly initiated. Although a transient improvement in clinical signs was observed on day 15 after hemophagocytic lymphohistiocytosis onset, recurrence of symptoms required the addition of etoposide (150 mg/m^2^) on day 24 after hemophagocytic lymphohistiocytosis onset. The patient received etoposide once every 3 days on 5 occasions; however, her symptoms recurred on day 56 after hemophagocytic lymphohistiocytosis onset, and she was transferred to our hospital on day 58 after hemophagocytic lymphohistiocytosis onset.

On admission, she was bedridden, had flaccid paralyses in her lower limbs, and could not maintain a sitting position. Although these neurological signs and symptoms were not recognized until the transfer, the mother had noticed symptoms such as her daughter's difficulty in standing up on day 5 after hemophagocytic lymphohistiocytosis onset. Evaluation of muscle strength was conducted according to the Medical Research Council muscle strength grading system; she was given grade 4 and grade 2 in the upper and lower extremities, respectively. Deep tendon reflexes were absent throughout. Cerebrospinal fluid examination on admission revealed 13 mg/dL of protein and 66 mg/dL of glucose, without an increase in cell numbers, and the patient was Epstein-Barr virus DNA negative. The antiganglioside antibodies in cerebrospinal fluid, such as immunoglobulin G and immunoglobulin M for GM1, GM2, GM3, GD1a, GD3, GalNAc-GD1a, GQ1b, GD1b, GT1b, and Gal-C, were all negative. Nerve conduction studies showed that the amplitude of the compound muscle action potential was severely decreased, and the pattern was almost compatible with acute motor axonal neuropathy. A diagnosis of Guillain-Barre syndrome was reached based on the clinical features and nerve conduction studies. Treatment with intravenous immunoglobulin G (0.4 g/kg/day for 5 days) was commenced on day 62 after hemophagocytic lymphohistiocytosis onset. On day 88 after hemophagocytic lymphohistiocytosis onset, the patient was able to maintain a sitting position, muscle strength had improved from grade 2 to grade 3, and the nerve conduction study pattern had normalized. However, to date, her neurological recovery is incomplete, and she is still unable to pull herself up.

For hemophagocytic lymphohistiocytosis, the patient received a THP-COP treatment regimen (pirarubicin 25 mg/m^2^ on days 1-2, cyclophosphamide 750 mg/m^2^, and vincristine 1.5 mg/m^2^ on day 1, and prednisone 50 mg/m^2^ on days 1-5). After this treatment, the Epstein-Barr virus copy number in her peripheral blood slightly decreased from 1 × 10^6^ copies/mL on admission to 2 × 10^5^ copies/mL. To reduce the Epstein-Barr virus copy number, 2 courses of ESCAP regimen (etoposide 150 mg/m^2^ on day 1, prednisone 30 mg/m^2^ on days 6-9, cytarabine 1.5 g/m^2^ × 2 on days 1-5, and L-asparaginase 6000 IU/m^2^ on days 5-9) were commenced on days 88 and 109 after hemophagocytic lymphohistiocytosis onset. The Epstein-Barr virus copy number increased after the second course of ESCAP, thus we are now in the process of coordinating unrelated umbilical cord blood transplantation. No correlation was detected between Epstein-Barr virus copy number and the degree of neurological symptoms.

Discussion {#section2-2329048X15620641}
==========

Epstein-Barr virus is a widely disseminated herpesvirus with approximately 90% to 95% of adults showing seropositivity. This virus sometimes causes serious complications including hemophagocytic lymphohistiocytosis and Guillain-Barre syndrome; the present case had a combination of these 2 rare complications.

As far as we investigated, PubMed database included 12 cases who had Guillain-Barre syndrome with proven Epstein-Barr virus infection. Of the 12 cases, only 2 had Epstein-Barr virus-hemophagocytic lymphohistiocytosis. Seven of the 12 cases achieved complete neurological recovery, 4 died because of Epstein-Barr virus infection, and only 1 resulted in a mild neurological sequela.

This is the first report of such a case in a child younger than 2 years of age. Childhood Guillain-Barre syndrome is a rare disease with an incidence of 0.5 to 2 cases per 100 000 children younger than 18 years old^[@bibr1-2329048X15620641],[@bibr2-2329048X15620641]^ and is especially rare in children younger than 2 years old. Although the reason for its rarity in younger children is unknown, one report has suggested that the difficulty in conducting a complete series of neurological examinations has resulted in underdiagnosis among the younger population.^[@bibr3-2329048X15620641]^

The presence of Epstein-Barr virus infection in Guillain-Barre syndrome is relatively rare. Clarence et al^[@bibr4-2329048X15620641]^ reported that the incidence rate of Epstein-Barr virus infection in Guillain-Barre syndrome was 0.36%. In our review, only 2 children, both older than 2 years, had Guillain-Barre syndrome accompanied by Epstein-Barr virus infection ([Table 1](#table1-2329048X15620641){ref-type="table"}; cases 2 and 7). On the other hand, Guillain-Barre syndrome accompanied by Epstein-Barr virus-hemophagocytic lymphohistiocytosis was rare based on our review, and only 2 reports have been published. We believe that the case reported here represents the youngest known patient with Guillain-Barre syndrome accompanied by Epstein-Barr virus-hemophagocytic lymphohistiocytosis.

###### 

Characteristics of the Patients With Guillain-Barre Syndrome Accompanied by Epstein-Barr Virus Infection.^a^

![](10.1177_2329048X15620641-table1)

  Case   Age, Years/Gender   EBV Infection            Subtype      Therapy       Outcome   Neurological Outcome                  Author (Year)
  ------ ------------------- ------------------------ ------------ ------------- --------- ------------------------------------- --------------------------------------------------------------
  1      78/M                HLH                      Unknown      IVIG + IVMP   CR        CR at 3 months                        Kaneko et al (1997)^[@bibr10-2329048X15620641]^
  2      11/M                HLH                      AIDP         --            Died      --                                    De Armas et al (2004)^[@bibr11-2329048X15620641]^
  3      47/M                LPD                      AMAN         IVIG          CR        CR at 9 months                        Hattori et al (2014)^[@bibr12-2329048X15620641]^
  4      29/M                IM                       AIDP         PE            CR        CR at 18 days                         Kennedy et al (2013)^[@bibr13-2329048X15620641]^
  5      72/M                CAEBV                    Unknown      IVIG          Died      --                                    Takahashi et al (2005)^[@bibr14-2329048X15620641]^
  6      46/M                Reactivation after BMT   Unknown      --            Died      --                                    Bitan et al (2004)^[@bibr15-2329048X15620641]^
  7      21M                 NS                       Unknown      IVIG          CR        CR at 3 months                        Young et al (2014)^[@bibr16-2329048X15620641]^
  8      63/M                NS                       AIDP         PE            CR        CR at 3 months                        Masajtis-Zagajewska et al (2012)^[@bibr17-2329048X15620641]^
  9      491M                NS                       AIDP         IVIG          CR        CR at l month                         Young et al (2008)^[@bibr18-2329048X15620641]^
  10     211M                NS                       Unknown      --            Died      --                                    Ringelstein et al (2012)^[@bibr19-2329048X15620641]^
  11     17/F                IM                       Unknown      IVIG + IVMP   CR        CR at 2 months                        Hojberg et al (2005)^[@bibr20-2329048X15620641]^
  12     18/M                IM                       AMSAN AIDP   PE            CR        Weak ankle dorsiflexion at 2 months   Gavin et al (1996)^[@bibr21-2329048X15620641]^
  13     1/F                 EBV-HLH                  AMAN         IVIG          --        Unable to stand up at 4 months        Present case

Abbreviations: LPD, lymphoproliferative disease; IM, infectious mononucleosis; CAEBV, chronic active Epstein-Barr virus infection; NS, not specified; AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; IVIG, intravenous immunoglobulin G; PE, plasma exchange; IVMP, pulsed methylprednisolone; CR, complete response; EBV, Epstein-Barr virus; HLH, hemophagocytic lymphohistiocytosis; BMT, bone marrow transplant; AMSAN, acute motor and sensory axonal neuropathy.

^a^ N = 13.

Generally, children with Guillain-Barre syndrome have a faster and better recovery than adults.^[@bibr5-2329048X15620641]^ Roodbol et al reported that all 37 pediatric patients with Guillain-Barre syndrome were able to walk independently within 1 year of disease onset, including those who were severely affected during the acute stage of the disease.^[@bibr6-2329048X15620641]^ In our review, only 1 of the 12 patients treated with plasma exchange or intravenous immunoglobulin G had a residual sequela. However, the child in the present case still has incomplete neurological recovery 4 months after the disease onset. We have 3 theories as to why this case is still affected by sequela. First, there is the possibility that nerve recovery was delayed because of the Guillain-Barre syndrome subtype. Nagasawa et al reported that cases with acute motor axonal neuropathy showed delayed recovery more frequently than acute inflammatory demyelinating polyneuropathy cases.^[@bibr7-2329048X15620641]^ Second, there is a possibility that a rapid progress in symptoms resulted in a poor prognosis. Although data regarding prognostic indicators of Guillain-Barre syndrome in children are limited, some reports suggest that progression to maximal weakness in less than 10 days constitutes a greater risk of long-term deficits (odds ratio, 1.8; 95% confidence interval, 1.06-3.67; *P* = .03).^[@bibr8-2329048X15620641]^ Third, the delay in treatment in our case could have resulted in incomplete nerve recovery.

The guidelines from the American Academy of Neurology recommend that intravenous immunoglobulin G for nonambulatory adult patients with Guillain-Barre syndrome should start within 2 to 4 weeks of the onset of neuropathic symptoms because the outcome is thought to be better for this group.^[@bibr9-2329048X15620641]^ In our case, muscle weakness symptoms progressed rapidly, and intravenous immunoglobulin G was commenced 2 months after the onset of neuropathic symptoms. It can be that the cause of the sequela in this case was due to the rapid progression of symptoms and the delay in treatment.

Both Epstein-Barr virus-hemophagocytic lymphohistiocytosis and Guillain-Barre syndrome can be fatal diseases. If they coexist, the balance of medical care in treating both diseases is very important. Treatment for hemophagocytic lymphohistiocytosis does not work for Guillain-Barre syndrome and vice versa. If a patient has neurological symptoms, there should be no hesitation in using invasive diagnostic procedures, such as nerve conduction study.

To the best of our knowledge, the authors report the youngest case of Guillain-Barre syndrome accompanied by Epstein-Barr virus-hemophagocytic lymphohistiocytosis. Rapid progression of Guillain-Barre syndrome, the electrophysiological subtype of Guillain-Barre syndrome, and treatment delay possibly led to poor neurological prognosis.
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